HK1247926A1 - 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 - Google Patents
四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 Download PDFInfo
- Publication number
- HK1247926A1 HK1247926A1 HK18107440.1A HK18107440A HK1247926A1 HK 1247926 A1 HK1247926 A1 HK 1247926A1 HK 18107440 A HK18107440 A HK 18107440A HK 1247926 A1 HK1247926 A1 HK 1247926A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- crystalline form
- diphenyl
- dimethyl
- disease
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0403—Solvent extraction of solutions which are liquid with a supercritical fluid
- B01D11/0411—Solvent extraction of solutions which are liquid with a supercritical fluid the supercritical fluid acting as solvent for the solvent and as anti-solvent for the solute, e.g. formation of particles from solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D9/00—Crystallisation
- B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195486P | 2015-07-22 | 2015-07-22 | |
| US62/195,486 | 2015-07-22 | ||
| PCT/IB2016/001181 WO2017013498A2 (en) | 2015-07-22 | 2016-07-19 | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1247926A1 true HK1247926A1 (zh) | 2018-10-05 |
Family
ID=57833871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18107440.1A HK1247926A1 (zh) | 2015-07-22 | 2016-07-19 | 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US10413519B2 (https=) |
| EP (2) | EP3325456B1 (https=) |
| JP (3) | JP7304043B2 (https=) |
| CN (2) | CN108026059A (https=) |
| CA (1) | CA2986349A1 (https=) |
| HK (1) | HK1247926A1 (https=) |
| WO (1) | WO2017013498A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108026059A (zh) * | 2015-07-22 | 2018-05-11 | 阿纳韦克斯生命科学公司 | 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 |
| US10426754B2 (en) | 2017-06-14 | 2019-10-01 | Anavex Life Sciences Corp. | Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease |
| JP2020523417A (ja) * | 2017-06-14 | 2020-08-06 | アナベックス ライフ サイエンス コーポレイション | アルツハイマー病の治療のためのａｎａｖｅｘ２−７３ |
| WO2019200345A1 (en) * | 2018-04-12 | 2019-10-17 | Anavex Life Sciences Corp. | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
| EP3794345B1 (en) | 2018-05-18 | 2025-02-26 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| US12473268B2 (en) | 2020-02-04 | 2025-11-18 | Assia Chemical Industries, Ltd. | Solid state forms of Blarcamesine salts |
| EP4516782A4 (en) | 2022-04-29 | 2025-06-11 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | CRYSTALLINE FORM OF BLARCAMESIN HYDROCHLORIDE, ITS PREPARATION PROCESS AND ITS USE |
| US12018005B1 (en) * | 2023-07-25 | 2024-06-25 | Egis Gyógyszergyár Zrt. | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9313642D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| GB9413202D0 (en) | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| GR1002616B (el) | 1996-02-21 | 1997-02-20 | Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης. | |
| GB9703673D0 (en) | 1997-02-21 | 1997-04-09 | Bradford Particle Design Ltd | Method and apparatus for the formation of particles |
| GB9804379D0 (en) | 1998-03-02 | 1998-04-22 | Bradford Particle Design Ltd | Method of particle formation |
| GB9810559D0 (en) | 1998-05-15 | 1998-07-15 | Bradford Particle Design Ltd | Method and apparatus for particle formation |
| GB9915975D0 (en) | 1999-07-07 | 1999-09-08 | Bradford Particle Design Ltd | Method for the formation of particles |
| GB0009803D0 (en) | 2000-04-25 | 2000-06-07 | Astrazeneca Ab | Chemical compounds |
| TW586963B (en) | 2001-07-20 | 2004-05-11 | Nektar Therapeutics Uk Ltd | Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus |
| US7368468B2 (en) | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
| GR1006794B (el) * | 2009-02-26 | 2010-06-04 | Αλεξανδρος Βαμβακιδης | Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση |
| GB201005623D0 (en) * | 2010-04-01 | 2010-05-19 | Vantia Ltd | New polymorph |
| GR1007686B (el) * | 2011-07-08 | 2012-09-12 | Αλεξανδρος Δημητριου Βαμβακιδης | Συνθεση των (+) και (-) 1-(5,5-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης, (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν,ν-διμεθυλομεθυλαμινης και (+) και (-) 1-(2,2-διφαινυλοτετραϋδροφουραν-3-υλ)-ν-μεθυλομεθυλαμινης |
| CN103539783A (zh) | 2012-07-12 | 2014-01-29 | 江苏恒瑞医药股份有限公司 | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 |
| GR1008233B (el) | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
| CN108026059A (zh) * | 2015-07-22 | 2018-05-11 | 阿纳韦克斯生命科学公司 | 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 |
| HK1247847A1 (zh) | 2015-07-22 | 2018-10-05 | 阿纳韦克斯生命科学公司 | 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 |
| US10426754B2 (en) | 2017-06-14 | 2019-10-01 | Anavex Life Sciences Corp. | Crystalline form of ANAVEX2-73 for the treatment of Alzheimer's disease |
-
2016
- 2016-07-19 CN CN201680033152.9A patent/CN108026059A/zh active Pending
- 2016-07-19 WO PCT/IB2016/001181 patent/WO2017013498A2/en not_active Ceased
- 2016-07-19 CA CA2986349A patent/CA2986349A1/en active Pending
- 2016-07-19 JP JP2017564733A patent/JP7304043B2/ja active Active
- 2016-07-19 CN CN202411518463.7A patent/CN119390667A/zh active Pending
- 2016-07-19 EP EP16827324.1A patent/EP3325456B1/en active Active
- 2016-07-19 US US15/579,705 patent/US10413519B2/en active Active
- 2016-07-19 EP EP25193445.1A patent/EP4616852A3/en active Pending
- 2016-07-19 HK HK18107440.1A patent/HK1247926A1/zh unknown
-
2019
- 2019-07-29 US US16/525,319 patent/US10966952B2/en active Active
-
2021
- 2021-02-08 JP JP2021018132A patent/JP2021073300A/ja active Pending
- 2021-04-05 US US17/222,611 patent/US11661405B2/en active Active
-
2023
- 2023-04-24 JP JP2023070740A patent/JP7492781B2/ja active Active
- 2023-05-08 US US18/313,723 patent/US20230278973A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2986349A1 (en) | 2017-01-26 |
| EP3325456A4 (en) | 2019-01-23 |
| US11661405B2 (en) | 2023-05-30 |
| JP7304043B2 (ja) | 2023-07-06 |
| US10966952B2 (en) | 2021-04-06 |
| US20190350892A1 (en) | 2019-11-21 |
| US20230278973A1 (en) | 2023-09-07 |
| EP4616852A2 (en) | 2025-09-17 |
| US20180169060A1 (en) | 2018-06-21 |
| EP3325456A2 (en) | 2018-05-30 |
| JP2023083528A (ja) | 2023-06-15 |
| WO2017013498A3 (en) | 2017-03-02 |
| JP7492781B2 (ja) | 2024-05-30 |
| JP2021073300A (ja) | 2021-05-13 |
| US20210220321A1 (en) | 2021-07-22 |
| US10413519B2 (en) | 2019-09-17 |
| CN119390667A (zh) | 2025-02-07 |
| JP2018524307A (ja) | 2018-08-30 |
| WO2017013498A2 (en) | 2017-01-26 |
| CN108026059A (zh) | 2018-05-11 |
| EP4616852A3 (en) | 2025-10-22 |
| EP3325456B1 (en) | 2025-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492781B2 (ja) | テトラヒドロ－ｎ，ｎ－ジメチル－２，２－ジフェニル－３－フランメタンアミンヒドロクロリドの結晶形態、かかる形態の作製方法およびその薬学的組成物 | |
| US10463644B2 (en) | Uses of sesquiterpene lactone compounds and their derivatives in drugs preparation | |
| JP2018511580A (ja) | イブルチニブの多形体 | |
| KR20170085590A (ko) | 신규 치환된 인다졸, 그의 제조 방법, 상기 신규 치환된 인다졸을 함유하는 제약 제제, 및 약물을 제조하기 위한 상기 신규 치환된 인다졸의 용도 | |
| Cheng et al. | Micronization of etoposide using solution-enhanced dispersion by supercritical CO2 | |
| EP3461818A1 (en) | Polymorphic forms of nilotinib hydrochloride | |
| CN104316608B (zh) | 阿齐沙坦酯杂质的检测及其制备方法 | |
| CN108727347B (zh) | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 | |
| JP2014141524A (ja) | ニコサミド（Ｎｉｃｏｕｓａｍｉｄｅ）化合物の五つの晶型、その製法やその薬物組合と用途 | |
| Zhao et al. | Co‐Crystal of Paracetamol and Trimethylglycine Prepared by a Supercritical CO2 Anti‐Solvent Process | |
| HK40121350A (zh) | 四氢-n，n-二甲基-2，2-二苯基-3-呋喃甲胺盐酸盐的晶型，制备这样晶型的方法，及其药物组合物 | |
| CN105418622B (zh) | 一种青蒿素衍生物及其合成方法和应用 | |
| Tjandrawinata et al. | Processing paracetamol-5-nitroisophthalic acid cocrystal using supercritical CO2 as an anti-solvent | |
| CN105793247B (zh) | 咪唑甲酰胺类及其作为faah抑制剂的用途 | |
| KR20260025092A (ko) | 글루타미닐 사이클라제 억제제 바로글루탐스타트의 결정질 약학적으로 허용 가능한 염 및 다형체 형태 | |
| CN106854203A (zh) | 枸橼酸舒芬太尼的新晶型及其制备方法 | |
| CN106336363B (zh) | 一种沙芬酰胺甲磺酸盐晶型c及其制备方法 | |
| CN107226784B (zh) | 超临界反溶剂造粒技术制备扑热息痛与甜菜碱共晶的方法 | |
| WO2015170827A1 (ko) | 실로도신 감마형 결정의 제조방법 | |
| JP2013518889A (ja) | （Ｓ）−１−（４−（５−シクロプロピル−１Ｈ−ピラゾール−３−イルアミノ）ピロロ［１，２−ｆ］［１，２，４］トリアジン−２−イル）−Ｎ−（６−フルオロピリジン−３−イル）−２−メチルピロリジン−２−カルボキサミドの結晶形 | |
| CN101384584A (zh) | 贝西吡啶盐酸盐的晶型、制备方法及其应用 | |
| HK40011956B (en) | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof | |
| HK40011956A (en) | Opioid receptor (mor) agonist salt, fumarate salt i crystal form thereof and preparation method thereof | |
| CN104797579A (zh) | 噻托溴铵溶剂化物的稳定化 | |
| CN106880635A (zh) | 一种环索奈德福莫特罗干粉吸入剂组合物 |